Capstone Therapeutics gets Nasdaq extension to Jan. 4, 2027 to regain $1 minimum bid compliance
PUBT · 3d ago
Share
Listen to the news
- Capstone Therapeutics Corporation won a further 180-day Nasdaq grace period to regain compliance with the $1 minimum bid price rule.
- New deadline set for Jan. 4, 2027; the bid-price threshold is its only remaining listing deficiency.
- Nasdaq granted the extension after the company met the public float value test, alongside other initial listing requirements.
- Shareholders authorized a potential reverse stock split of 1-for-5 to 1-for-50 if needed to lift the share price.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607090835BIZWIRE_USPR_____20260709_BW033412) on July 09, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved